StimCardio Raises $30 Million in Series A

The Los Angeles medical device company will use the funding to advance its wearable therapy for atrial fibrillation toward a pivotal study.

Updated on Nov. 17, 2026 in Diseases

StimCardio Raises $30 Million in Series A

Los Angeles-based StimCardio, a clinical-stage medical device company, has raised $30 million in Series A financing led by John Slump's family office and Metis Medtech. The company develops non-invasive wearable therapeutics for atrial fibrillation, with its lead product, Rhyvive, delivering personalized median nerve stimulation through a closed-loop system.

Why it matters

Atrial fibrillation is a common heart rhythm disorder, and the financing supports a therapy designed to work alongside catheter ablation and extend treatment into the patient's home. The raise moves the company toward a planned pivotal study that will test whether adding wearable neuromodulation to ablation improves clinical outcomes.

StimCardio reported a $30 million Series A round, the financing's headline figure, with no comparator provided. Its prior NeuroPulse 1 pilot showed a statistically significant reduction in recurrent atrial arrhythmia events after ablation with active stimulation versus sham, though the extraction does not give effect sizes or sample counts.

The players

StimCardio

A Los Angeles-based clinical-stage medical device company developing non-invasive wearable therapeutics for atrial fibrillation.

Metis Medtech

A medical technology investment firm that co-led the financing round for StimCardio.

The details

The Series A was led by John Slump's family office and Metis Medtech, with Catalyst Health Ventures, several corporate strategic investors and other investors also participating. StimCardio presented its NeuroPulse 1 pilot study as a late-breaking clinical trial at HRX Live 2026, and the results were published in Heart Rhythm.

Timeline

  1. HRX Live 2026: NeuroPulse 1 presented as a late-breaking clinical trial.

  2. November 17, 2026: StimCardio announced the $30 million Series A financing.

Health Landscape

The financing follows the NeuroPulse 1 pilot, published in Heart Rhythm, which reported fewer recurrent atrial arrhythmia events after ablation with active median nerve stimulation than with sham. The planned NeuroPulse 2 pivotal trial would test whether that adjunctive approach improves outcomes across a larger, multicenter population.

If approved, Rhyvive would give patients with atrial fibrillation a wrist-worn option to continue treatment at home after catheter ablation rather than relying only on in-clinic procedures. Whether the therapy reaches patients, and on what timeline, depends on the outcome of the planned pivotal trial and FDA review.

The takeaway

Wearable neuromodulation is being tested as an add-on to standard heart rhythm procedures, not a replacement, so its value will depend on whether larger trials show better outcomes than ablation alone.

What happens next

StimCardio plans to launch the NeuroPulse 2 pivotal study and submit a De Novo request to the FDA, though the extraction gives no dates for either step.

Further reading

For broader context on treatments for irregular heartbeats, explore Heart Disease coverage on Wisevoter.

Source note: This article includes information reported by Los Angeles Times.